Clarence Ahlem
Direttore operativo presso NeurMedix, Inc.
Patrimonio netto: 18 165 $ in data 30/04/2024
Profilo
Clarence Ahlem currently works at NeurMedix, Inc., as Chief Operating Officer.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
BIOVIE INC. CLASS A
0.07% | 16/02/2023 | 37 148 ( 0.07% ) | 18 165 $ | 30/04/2024 |
Posizioni attive di Clarence Ahlem
| Società | Posizione | Inizio |
|---|---|---|
NeurMedix, Inc.
 NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
NeurMedix, Inc.
NeurMedix, Inc. Pharmaceuticals: MajorHealth Technology NeurMedix, Inc. is a clinical-stage biopharmaceutical company that develops products for the treatment of neurological and neuro-degenerative disorders and certain cancers. NeurMedix is based in San Diego, CA, and was founded by Terren S. Peizer, who has been the CEO since incorporation. The private company's product candidates have completed several pre-clinical and clinical studies, indicating its broad anti-inflammatory effect without evidence of immunosuppression. NeurMedix has invested over $85 million in developing NE3107, and its focus is on diseases with significant unmet medical needs and commercial potential. The company plans to enter clinical trials for the treatment of Parkinson's disease and several oncological indications later this year. | Health Technology |
- Borsa valori
- Insiders
- Clarence Ahlem
